UPXI on Nasdaq
UPEXI, INC.
UPEXI, INC. is an American finance services company based in Tampa, listed on Nasdaq (UPXI).2
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Forward Industries, Inc., BTCS Inc. or OpenWorld, Inc., or pick any stock.
- TickerUPXI on Nasdaq2
- IndustryFinance Services2
- HeadquartersTampa, United States2
- Incorporated inDE4
- Business address3030 N. Rocky Point Drive, Suite 420, Tampa, Fl4
- Filer categoryNon-accelerated filer, Smaller reporting company4
- Legal formCorporation2
- LEI529900DXT4FO60PCDE092
- StatusActive2
- LEI statusIssued and current2
- Registered addressc/o VCORP AGENT SERVICES, INC.,108 W. 13TH STREET SUITE 100, 19801 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 102442672
See how the biggest companies compare on our leaderboards
We are in the cryptocurrency industry and the management of cash assets through a cryptocurrency portfolio, primarily focused in Solana tokens and generating a yield from the treasury, primarily through staking of those tokens. We continue to be brand owners, selling our products wholesale and direct to consumers. Distribution and fulfillment of our products is done by a third-party specializing in these services.6 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2026
Where the money goes
Where each dollar of revenue went, fiscal 2026
- Cost of revenue15¢$2.6M
- Other costs85¢$14.7M
- Interest0¢$62.7K
Out of $17.4M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.3
| Period ending | 2026-06-30 | 2025-06-30 |
|---|---|---|
| Revenue | $7.6M | $14.8M |
| Digital asset revenue | $17.4M | $985.0K |
| Total revenue | $25.0M | $15.8M |
| Cost of revenue | $2.6M | $4.9M |
| Gross profit | $22.4M | $10.9M |
| Sales and marketing | $2.9M | $4.0M |
| Distribution costs | $2.6M | $4.7M |
| General and administrative | $26.4M | $11.9M |
| Unrealized loss (gain) on digital assets | $195.1M | -$105.5K |
| Realized loss on digital asset revenue conversion to USD | $4.9M | $0 |
| Realized loss on sale of digital assets | $6.8M | $0 |
| Stock-based compensation | $21.9M | $2.4M |
| Amortization of acquired intangible assets | $76.8K | $76.8K |
| Impairment on assets from manufacturing shut down | $1.4M | $0 |
| Impairment on acquired intangible assets | $750.0K | $0 |
| Depreciation | $379.5K | $681.0K |
| Lease Impairment (gain on settlement), Delray Beach facility | $0 | -$270.0K |
| Total operating expenses | $263.2M | $23.4M |
| Loss from operations | -$240.8M | -$12.5M |
| Interest expense, net | -$13.6M | -$1.2M |
| Gain on extinguishment of debt | $10.3M | $0 |
| Other expense, net | -$1.9M | -$10.7K |
| Other expense, net | -$5.2M | -$1.2M |
| Loss on operations before income tax | -$246.1M | -$13.7M |
| Income tax benefit (expense) | $0 | $0 |
| Net loss | -$246.1M | -$13.7M |
| Loss per share | -$3.87 | -$1.73 |
| Loss per share | -$3.87 | -$1.73 |
| Basic weighted average shares outstanding | 63.5M shares | 7.9M shares |
| Fully diluted weighted average shares outstanding | 63.5M shares | 7.9M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.3
| Period ending | 2026-06-30 | 2025-06-30 | 2024-06-30 |
|---|---|---|---|
| Cash | $5.8M | $3.0M | $661.4K |
| Accounts receivable, net | $97.2K | $157.5K | |
| Inventory, net | $266.0K | $1.2M | |
| Due from VitaMedica transition | $10.8K | $228.0K | |
| Prepaid expenses and other assets | $988.5K | $350.8K | |
| Current digital assets at fair value | $109.6M | $49.9M | |
| Purchase price receivable - VitaMedica | $0 | $2.0M | |
| Total current assets | $116.8M | $56.8M | |
| Property and equipment, net | $208.0K | $2.1M | |
| Intangible assets, net | $86.4K | $163.1K | |
| Goodwill | $673.9K | $848.9K | |
| Deferred tax asset | $5.9M | $5.9M | |
| Digital assets at fair value, net of current | $55.7M | $56.1M | |
| Other assets | $163.2K | $192.1K | |
| Right-of-use asset, net | $598.7K | $1.7M | |
| Total noncurrent assets | $63.4M | $67.0M | |
| Total assets | $180.1M | $123.8M | |
| Accounts payable | $277.6K | $1.0M | |
| Accrued compensation | $5.3M | $3.5M | |
| Deferred revenue | $4.5K | $13.2K | |
| Accrued liabilities | $1.7M | $356.1K | |
| Accrued interest | $2.3M | $792.4K | |
| Acquisition payable | $260.7K | $260.7K | |
| Current portion of promissory notes | $0 | $560.0K | |
| Short-term treasury debt | $57.3M | $20.0M | |
| Current portion of Cygnet subsidiary notes payable | $3.7M | $5.4M | |
| Current portion of operating lease payable | $295.2K | $691.0K | |
| Total current liabilities | $71.1M | $32.6M | |
| Operating lease payable, net of current portion | $362.2K | $1.1M | |
| Convertible notes payable | $162.4M | $0 | |
| Total long-term liabilities | $162.8M | $1.1M | |
| Preferred stock, $0.00001 par value, 10,000,000 shares authorized, and 150,000 shares issued and outstanding | $2 | $2 | |
| Common stock, $0.00001 par value, 1,000,000,000 shares authorized, 78,702,358 and 38,270,571 shares issued and outstanding, as of June 30, 2026 and June 30, 2025, respectively | $787 | $383 | |
| Additional paid in capital | $252.8M | $150.6M | |
| Accumulated deficit | -$306.6M | -$60.5M | |
| Total stockholders' equity | -$53.8M | $90.1M | $6.5M |
| Total liabilities and stockholders' equity | $180.1M | $123.8M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued | 150.0K shares | 150.0K shares | |
| Preferred stock, shares outstanding | 150.0K shares | 150.0K shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 1.0B shares | 1.0B shares | |
| Common stock, shares issued | 78.7M shares | 38.3M shares | |
| Common stock, shares outstanding | 78.7M shares | 38.3M shares |
| Period ending | 2026-06-30 | 2025-06-30 | 2024-06-30 |
|---|---|---|---|
| Cash | $5.8M | $3.0M | $661.4K |
| Accounts receivable, net | $97.2K | $157.5K | |
| Inventory, net | $266.0K | $1.2M | |
| Due from VitaMedica transition | $10.8K | $228.0K | |
| Prepaid expenses and other assets | $988.5K | $350.8K | |
| Current digital assets at fair value | $109.6M | $49.9M | |
| Purchase price receivable - VitaMedica | $0 | $2.0M | |
| Total current assets | $116.8M | $56.8M | |
| Property and equipment, net | $208.0K | $2.1M | |
| Intangible assets, net | $86.4K | $163.1K | |
| Goodwill | $673.9K | $848.9K | |
| Deferred tax asset | $5.9M | $5.9M | |
| Digital assets at fair value, net of current | $55.7M | $56.1M | |
| Other assets | $163.2K | $192.1K | |
| Right-of-use asset, net | $598.7K | $1.7M | |
| Total noncurrent assets | $63.4M | $67.0M | |
| Total assets | $180.1M | $123.8M | |
| Accounts payable | $277.6K | $1.0M | |
| Accrued compensation | $5.3M | $3.5M | |
| Deferred revenue | $4.5K | $13.2K | |
| Accrued liabilities | $1.7M | $356.1K | |
| Accrued interest | $2.3M | $792.4K | |
| Acquisition payable | $260.7K | $260.7K | |
| Current portion of promissory notes | $0 | $560.0K | |
| Short-term treasury debt | $57.3M | $20.0M | |
| Current portion of Cygnet subsidiary notes payable | $3.7M | $5.4M | |
| Current portion of operating lease payable | $295.2K | $691.0K | |
| Total current liabilities | $71.1M | $32.6M | |
| Operating lease payable, net of current portion | $362.2K | $1.1M | |
| Convertible notes payable | $162.4M | $0 | |
| Total long-term liabilities | $162.8M | $1.1M | |
| Preferred stock, $0.00001 par value, 10,000,000 shares authorized, and 150,000 shares issued and outstanding | $2 | $2 | |
| Common stock, $0.00001 par value, 1,000,000,000 shares authorized, 78,702,358 and 38,270,571 shares issued and outstanding, as of June 30, 2026 and June 30, 2025, respectively | $787 | $383 | |
| Additional paid in capital | $252.8M | $150.6M | |
| Accumulated deficit | -$306.6M | -$60.5M | |
| Total stockholders' equity | -$53.8M | $90.1M | $6.5M |
| Total liabilities and stockholders' equity | $180.1M | $123.8M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued | 150.0K shares | 150.0K shares | |
| Preferred stock, shares outstanding | 150.0K shares | 150.0K shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 1.0B shares | 1.0B shares | |
| Common stock, shares issued | 78.7M shares | 38.3M shares | |
| Common stock, shares outstanding | 78.7M shares | 38.3M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.3
| Period ending | 2026-06-30 | 2025-06-30 |
|---|---|---|
| Net loss | -$246.1M | -$13.7M |
| Depreciation and amortization | $456.2K | $757.8K |
| Unrealized loss (gain) on digital assets | $195.1M | -$101.3K |
| Realized loss on sale of digital assets | $6.8M | $0 |
| Digital asset revenue | -$17.4M | -$985.0K |
| Digital asset revenue conversion to USD | $13.2M | $0 |
| Realized loss on digital asset revenue conversion to USD | $4.9M | $0 |
| Amortization of loan costs | $3.7M | $30.5K |
| Loss on disposal of property and equipment | $237.7K | $10.7K |
| Gain on extinguishment of debt | -$10.3M | $0 |
| Inventory write-off | $0 | $748.9K |
| Bad debt reserve for Amazon receivable | $0 | $934.0K |
| Reduction of acquisition payable | $0 | -$152.5K |
| Lease impairment (gain on settlement) | $0 | -$270.0K |
| Impairment on assets from manufacturing shut down | $1.4M | $0 |
| Impairment on acquired intangible assets | $750.0K | $0 |
| Issuance of stock for services | $0 | $250.0K |
| Stock-based compensation | $21.9M | $2.1M |
| Accounts receivable | $60.3K | -$484.6K |
| Inventory | $886.9K | -$470.2K |
| Prepaid expenses and other assets | -$411.6K | $222.0K |
| Operating lease payable | -$26.7K | $21.0K |
| Accounts payable and accrued liabilities | $4.0M | $2.9M |
| Deferred revenue | -$8.6K | -$222.1K |
| Net cash used in operating activities | -$21.0M | -$8.4M |
| Proceeds from the sale of building | $0 | $4.0M |
| Proceeds from the sale of E-core | $0 | $2.0M |
| Proceeds from the sale of MW Products assets | $175.0K | $0 |
| Proceeds from the sale of VitaMedica, Inc. | $2.0M | $0 |
| Acquisition of digital assets | -$40.0M | -$104.9M |
| Proceeds from the sale of digital assets | $8.0M | $0 |
| Acquisition of royalty interest | -$750.0K | $0 |
| Acquisition of property and equipment | -$44.0K | -$387.8K |
| Net cash used in investing activities | -$30.6M | -$99.3M |
| Proceeds from issuance of common stock | $75.2M | $92.6M |
| Issuance of preferred stock series A | $0 | $325.0K |
| Proceeds from exercise of warrants | $107.9K | $250.0K |
| Repurchases of common stock | -$2.8M | $0 |
| Proceeds from short-term treasury debt | $5.0M | $0 |
| Repayment of short-term treasury debt | -$10.4M | $0 |
| Proceeds from issuance of convertible notes | $0 | $350.0K |
| Repayment of promissory notes | -$560.0K | $0 |
| Proceeds from related party advance | $0 | $75.0K |
| Repayment of related party advance | $0 | -$175.0K |
| Payments of equity issuance costs | -$4.5M | $0 |
| Payments of debt issuance costs | -$7.6M | $0 |
| Payment on acquisition notes payable | $0 | -$66.7K |
| Payment on convertible note | $0 | -$150.0K |
| Proceeds from issuance of short-term debt | $0 | $20.0M |
| Repayment of related party note payable | $0 | -$500.0K |
| Repayment on note payable on building | $0 | -$2.6M |
| Net cash provided by financing activities | $54.4M | $110.0M |
| Net increase in cash | $2.8M | $2.3M |
| Interest paid | $8.4M | $805.9K |
| Income tax paid | $11.3K | $0 |
| Issuance of common stock for the repayment of convertible notes payable | $12.3M | $1.8M |
| Issuance of convertible debt for digital assets acquired | $187.1M | $0 |
| Issuance of short-term debt for digital assets acquired | $42.7M | $0 |
No quarter-by-quarter statement was filed.
Corporate structure
UPEXI, INC. sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of UPEXI, INC.
- Hivemind Capital Partners, LLC Filed SCHEDULE 13G/A on UPEXI, INC., latest Aug 14, 2026 (2 filings since Aug 14, 2026)
- VANGUARD CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G/A on UPEXI, INC., latest Jul 31, 2026 (2 filings since Apr 30, 2026)
- GSR Growth Investments LP Filed SCHEDULE 13G/A on UPEXI, INC., latest Jul 24, 2026 (4 filings since Apr 30, 2025)
- Polar Asset Management Partners Inc. Filed SCHEDULE 13G/A on UPEXI, INC., latest May 15, 2026 (3 filings since Nov 14, 2025)
- MMCAP International Inc. SPC Filed SCHEDULE 13G/A on UPEXI, INC., latest Feb 13, 2026 (2 filings since Jul 22, 2025)
- Kathmere Capital Management, LLC Filed SCHEDULE 13G/A on UPEXI, INC., latest Feb 11, 2026 (2 filings since Jul 30, 2025)
- Marex Securities Products Inc. Filed SCHEDULE 13G on UPEXI, INC., latest Jan 8, 2026
- Attestor Value Master Fund, LP Filed SCHEDULE 13G on UPEXI, INC., latest Oct 16, 2025 (2 filings since Jul 11, 2025)
- Michael Novogratz Filed SCHEDULE 13G/A on UPEXI, INC., latest Aug 5, 2025 (2 filings since May 1, 2025)
- Robert Hackett Filed SC 13G on UPEXI, INC., latest Jun 1, 2023 (2 filings since Feb 14, 2022)
- Allan Marshall Filed SC 13G/A on UPEXI, INC., latest Mar 10, 2023 (2 filings since Feb 14, 2022)
- Andrew James Norstrud Filed SC 13G on UPEXI, INC., latest Mar 10, 2023
- UPEXI, INC. Tampa, Florida, United States
- Upexi 17129 Subsidiary · Florida, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What UPEXI, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $402.9K3 Jun 30, 2026 | $4.0M3 Jun 30, 2025 | −89.9% |
| Property and equipment, net | $208.0K3 Jun 30, 2026 | $2.1M3 Jun 30, 2025 | −89.9% |
| Operating-lease assets (leased space) | $598.7K3 Jun 30, 2026 | $1.7M3 Jun 30, 2025 | −65.6% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $673.9K3 Jun 30, 2026 | $848.9K3 Jun 30, 2025 | −20.6% |
| Intangible assets, net (excluding goodwill) | $86.4K3 Jun 30, 2026 | $163.1K3 Jun 30, 2025 | −47.1% |
| Finite-lived intangibles, gross | $383.8K3 Jun 30, 2026 | $10.0M3 Jun 30, 2025 | −96.2% |
| Accumulated amortization | $297.4K3 Jun 30, 2026 | $9.9M3 Jun 30, 2025 | −97.0% |
| Finite-lived intangibles, net | $86.4K3 Jun 30, 2026 | $163.1K3 Jun 30, 2025 | −47.1% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $266.0K3 Jun 30, 2026 | $1.2M3 Jun 30, 2025 | −76.9% |
| Raw materials | $03 Jun 30, 2026 | $489.6K3 Jun 30, 2025 | −100.0% |
| Finished goods | $266.0K3 Jun 30, 2026 | $663.3K3 Jun 30, 2025 | −59.9% |
Properties, in its own words
Our corporate headquarters consists of approximately 5,752 square feet of leased office space located at 3030 North Rocky Point Drive, Suite 420, Tampa, Florida 33607. We also lease additional office space at 3030 North Rocky Point Drive, Suite 480, Tampa, Florida 33607. The lease for Suite 420 expires on September 1, 2028, and the lease for Suite 480 expires on October 1, 2028.
Item 2 of the 10-K filed Sep 17, 2026.6
Leadership
Who has led UPEXI, INC., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
- Chief executive officerAllan Marshall Jun 24, 2021 to now14
- PresidentRobert Hackett Jun 24, 2021 to Jun 24, 202115
- Chief financial officerAndrew James Norstrud Jun 24, 2021 to now16
Board members and other officers (8)
- CSOBrian Benjamin Rudick Jun 3, 2025 to now17
- Chief Operations OfficerAnthony P. Bazan Sep 8, 2022 to Sep 8, 202218
- Board memberAndrew James Norstrud Apr 25, 2025 to now19
- Board memberAllan Marshall Jun 24, 2021 to now14
- Board memberGene Salkind Jun 24, 2021 to now20
- Board memberLawrence Dugan Jun 24, 2021 to now21
- Board memberRobert Hackett Jun 24, 2021 to Jun 24, 202115
- Board memberThomas Charles Williams Jun 24, 2021 to now22
Named in SEC Form D filings
People the company listed in its private-offering notices.
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Upexi 17129 Florida, LLC5
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- GROVE, INC.Apr 30, 2019 to Aug 16, 20224
Timeline
- Oct 13, 20268-K Regulation FD disclosure25
- Oct 7, 20268-K Other events26
- Sep 17, 20268-K Results of operations27
- Sep 15, 20268-K Regulation FD disclosure28
- Sep 14, 20268-K Entered a material agreement; Regulation FD disclosure29
- Sep 9, 20268-K Other events30
- Jul 31, 20268-K Listing notice or transfer31
- Jun 30, 20268-K Other events32
- Jun 26, 20268-K Listing notice or transfer; Other events33
- Jun 25, 20268-K Entered a material agreement; Unregistered sale of shares34
- Jun 24, 20268-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure35
- Jun 16, 20268-K Shareholder vote36
- Jun 30, 2025Founded UPEXI, INC. is founded2
- Jun 24, 2021New chief executive Allan Marshall becomes CEO14
Calendar
Coming up
- Nov 10, 2026Reports results for the quarter ending Sep/202637
When it reported results
- Sep 17, 2026Reported quarterly or annual results27
- May 13, 2026Reported quarterly or annual results38
- Feb 10, 2026Reported quarterly or annual results39
- Nov 12, 2025Reported quarterly or annual results40
- Sep 26, 2025Reported quarterly or annual results41
- May 16, 2025Reported quarterly or annual results42
- Dec 23, 2024Reported quarterly or annual results43
- Jul 11, 2024Reported quarterly or annual results44
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
348 filings to the SEC since October 2021: 6 annual reports, 16 quarterly reports, 167 major events, 39 insider forms, 28 large holders, 4 private raises, 88 other. The latest 20:
- Oct 13, 20268-K EDGAR
- Oct 13, 2026DEF 14A EDGAR
- Oct 7, 20268-K EDGAR
- Sep 29, 2026PRE 14A EDGAR
- Sep 17, 20268-K EDGAR
- Sep 17, 202610-K EDGAR
- Sep 15, 20268-K EDGAR
- Sep 14, 20268-K EDGAR
- Sep 9, 20268-K EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 14, 2026SCHEDULE 13G EDGAR
- Jul 31, 2026SCHEDULE 13G/A EDGAR
- Jul 31, 20268-K EDGAR
- Jul 24, 2026SCHEDULE 13G/A EDGAR
- Jul 20, 20264 EDGAR
- Jul 20, 20264 EDGAR
- Jul 20, 20264 EDGAR
- Jul 20, 20264 EDGAR
- Jul 20, 20264 EDGAR
- Jul 16, 2026EFFECT EDGAR
The 348 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
36 open-market trades by officers, directors and large owners since October 2021: 36 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Dec 23, 2025 | MARSHALL ALLANChief Executive Officer | Buy | 50,000 | $1.80 | $90.0K | Form 4 |
| Dec 16, 2025 | MARSHALL ALLANChief Executive Officer | Buy | 50,000 | $2.07 | $103.5K | Form 4 |
| Dec 15, 2025 | MARSHALL ALLANChief Executive Officer | Buy | 100,000 | $2.07 | $207.0K | Form 4 |
| Nov 20, 2025 | Salkind GeneDirector | Buy | 50,000 | $2.55 | $127.5K | Form 4 |
| Nov 17, 2025 | Salkind GeneDirector | Buy | 200,000 | $2.73 | $546.0K | Form 4 |
| Jul 22, 2025 | Dugan LawrenceDirector | Buy | 4,000 | $7.50 | $30.0K | Form 4 |
| Jul 16, 2025 | Dugan LawrenceDirector | Buy | 11,000 | $5.69 | $62.6K | Form 4 |
| Jul 15, 2025 | Dugan LawrenceDirector | Buy | 1,000 | $5.17 | $5.2K | Form 4 |
| Jul 11, 2025 | Salkind GeneDirector | Buy | 20,243 | $4.94 | $100.0K | Form 4 |
| Jul 11, 2025 | MARSHALL ALLANChief Executive Officer | Buy | 161,943 | $4.94 | $800.0K | Form 4 |
| Apr 17, 2025 | MARSHALL ALLANChief Executive Officer | Buy | 657,895 | $2.28 | $1.5M | Form 4 |
| Apr 17, 2025 | Norstrud Andrew JamesChief Financial Officer | Buy | 43,860 | $2.28 | $100.0K | Form 4 |
| Apr 17, 2025 | Salkind GeneDirector | Buy | 241,229 | $2.28 | $550.0K | Form 4 |
| Mar 12, 2024 | MARSHALL ALLANChief Executive Officer | Buy | 64,150 | $0.57 | $36.6K | Form 4 |
| Mar 11, 2024 | MARSHALL ALLANChief Executive Officer | Buy | 13,623 | $0.60 | $8.2K | Form 4 |
| Mar 5, 2024 | MARSHALL ALLANChief Executive Officer | Buy | 103,013 | $0.70 | $72.1K | Form 4 |
| Dec 15, 2023 | MARSHALL ALLANChief Executive Officer | Buy | 4,535 | $0.91 | $4.1K | Form 4 |
| Dec 14, 2023 | MARSHALL ALLANChief Executive Officer | Buy | 8,381 | $0.98 | $8.2K | Form 4 |
| Dec 7, 2023 | MARSHALL ALLANChief Executive Officer | Buy | 90,001 | $0.94 | $84.6K | Form 4 |
| Dec 5, 2023 | MARSHALL ALLANChief Executive Officer | Buy | 19,296 | $0.84 | $16.2K | Form 4 |
All 36 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Hivemind Capital Partners, LLCSCHEDULE 13G/A, 2 filings Aug 14, 202645
- VANGUARD CAPITAL MANAGEMENT LLCSCHEDULE 13G/A, 2 filings Apr 30, 2026 to Jul 31, 202646
- GSR Growth Investments LPSCHEDULE 13G/A, 4 filings Apr 30, 2025 to Jul 24, 202647
- Polar Asset Management Partners Inc.SCHEDULE 13G/A, 3 filings Nov 14, 2025 to May 15, 202648
- MMCAP International Inc. SPCSCHEDULE 13G/A, 2 filings Jul 22, 2025 to Feb 13, 202649
- Kathmere Capital Management, LLCSCHEDULE 13G/A, 2 filings Jul 30, 2025 to Feb 11, 202650
- Marex Securities Products Inc.SCHEDULE 13G, 1 filing Jan 8, 202651
- Attestor Value Master Fund, LPSCHEDULE 13G, 2 filings Jul 11, 2025 to Oct 16, 202552
- Michael NovogratzSCHEDULE 13G/A, 2 filings May 1, 2025 to Aug 5, 202553
- Robert HackettSC 13G, 2 filings Feb 14, 2022 to Jun 1, 202354
- Allan MarshallSC 13G/A, 2 filings Feb 14, 2022 to Mar 10, 202355
- Andrew James NorstrudSC 13G, 1 filing Mar 10, 202356
- Gene SalkindSC 13G/A, 2 filings Feb 14, 2022 to Mar 10, 202357
- Jeffrey Michael BishopSC 13G, 1 filing Feb 10, 202258
Money raised
Private offerings the company reported to the SEC on Form D.
- Jun 21, 2026Raised $19.5 million in a private offering of securities Form D: 1 investor so far Form D
- Jul 11, 2025Raised $200 million in a private offering of equity Form D: 1 investor so far Form D
- Apr 24, 2025Raised $100 million in a private offering of equity Form D: 73 investors so far Form D
- Oct 19, 2021Raised $4 million in a private offering of equity Form D: 2 investors so far Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 47. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Arrington Capital Management, LLC | 2,760,107 | $2.2M | 2.4% | No change |
| Vanguard Capital Management LLC | 2,409,720 | $1.9M | 0.0% | −972,882 |
| MMCAP International Inc. SPC | 2,326,777 | $1.8M | 0.2% | No change |
| BlackRock, Inc. | 888,906 | $697.1K | 0.0% | +207,598 |
| Osaic Holdings, Inc. | 770,236 | $600.8K | 0.0% | −5,626 |
| Susquehanna International Group, Llp | 703,129 | $551.4K | 0.0% | +4,401 |
| Geode Capital Management, LLC | 582,895 | $457.4K | 0.0% | +44,378 |
| Vanguard Fiduciary Trust Co | 311,362 | $244.1K | 0.0% | −16,621 |
| Millennium Management LLC | 271,216 | $212.7K | 0.0% | −22,968 |
| UBS Group AG | 232,206 | $182.0K | 0.0% | −533,570 |
| XTX Topco Ltd | 229,653 | $180.1K | 0.0% | +110,199 |
| State Street Corp | 192,022 | $150.6K | 0.0% | No change |
| Jane Street Group, LLC | 191,536 | $150.2K | 0.0% | +841 |
| J. Derek Lewis & Associates Inc. | 125,000 | $98.0K | 0.0% | +28,000 |
| Northern Trust Corp | 117,311 | $92.0K | 0.0% | +9,091 |
| Citadel Advisors LLC | 100,402 | $78.7K | 0.0% | New |
| Citigroup Inc | 79,135 | $62.1K | 0.0% | +79,130 |
| Engineers Gate Manager LP | 77,738 | $61.0K | 0.0% | +24,885 |
| Pinnacle Financial Partners, Inc. | 70,720 | $55.5K | 0.0% | No change |
| Goldman Sachs Group Inc | 68,378 | $53.6K | 0.0% | +46,187 |
| IMC-Chicago, LLC | 52,768 | $41.4K | 0.0% | +4,698 |
| Millington Financial Advisors, LLC | 40,000 | $32.2K | 0.0% | No change |
| Commonwealth Equity Services, LLC | 33,125 | $26.0K | 0.0% | +500 |
| Morgan Stanley | 27,166 | $21.3K | 0.0% | +20,066 |
| Cetera Investment Advisers | 24,207 | $19.0K | 0.0% | No change |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How UPEXI, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARUPEXI, INC.1
- CIK0001775194
- Employer ID (EIN)83-33789786
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company6
- Incorporated inDelaware6
- Fiscal year endsJune 301
- Industry code (SIC)6199 Finance Services1
- SEC reviewing officeOffice of Crypto Assets, Division of Corporation Finance1
- Business address3030 N. Rocky Point Drive, Suite 420, Tampa, FL1
- Phone727-287-28001
- Shares outstanding82,102,474 shares as of Sep 15, 20266
- Public float$101.2M as of Dec 31, 20256
- AuditorGBQ Partners LLC, Columbus, Ohio PCAOB ID 18086
- On EDGAR sinceApr 30, 20191
- Filings396 in all: 8-K (169), 4 (42), CORRESP (19), S-1/A (18), 10-Q (15), UPLOAD (15), SCHEDULE 13G (10), SCHEDULE 13G/A (10)1
All 39 form types
3 (8), DEF 14A (8), EFFECT (8), 424B3 (7), 10-K (6), D (6), SC 13G (6), 8-K/A (5), NT 10-Q (5), S-1 (5), PRE 14A (4), S-3 (4), 424B5 (3), S-8 (3), 3/A (2), NT 10-K (2), SC 13G/A (2), 10-K/A (1), 10-Q/A (1), 424B4 (1), 424B7 (1), 8-A12B (1), CERT (1), DEF 14C (1), DEFR14A (1), DRS (1), DRS/A (1), DRSLTR (1), FWP (1), POS AM (1), PRE 14C (1)
- Latest filingsAnnual report (10-K) Sep 17, 2026
Quarterly report (10-Q) May 12, 2026
Proxy statement (DEF 14A) Oct 13, 2026
Latest 8-K (8-K) Oct 13, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, par value $0.00001 | UPXI | NASDAQ |
From the cover page of the 10-K filed Sep 17, 2026 (Section 12(b) of the Exchange Act).6
Risk factors and legal proceedings
The risks UPEXI, INC. names in Item 1A of its 10-K filed Sep 17, 2026: 49 risks under these headings, as written.6
- Risks Related to Upexi
- Upexi does not anticipate paying any dividends on its common stock.
- You may experience additional dilution in the future.
- Shares eligible for future sale may adversely affect the market.
- Our limited operating history makes it difficult for potential investors to evaluate our business prospects and management.
- If we are unable to protect our intellectual property rights, our competitive position could be harmed.
- We may not be able to effectively manage growth.
- Our management may not be able to control costs in an effective or timely manner.
- We expect our quarterly financial results to fluctuate.
- We are subject to the reporting requirements of U.S. federal securities laws, which can be expensive.
- Cybersecurity breaches of our IT systems could degrade our ability to conduct our business operations and deliver products and services to our customers, delay our ability to recognize revenue, compromise the integrity of our software products, result in significant data losses and the theft of our intellectual property, damage our reputation, expose us to liability to third parties and require us to incur significant additional costs to maintain the security of our networks and data.
- We may incur significant costs and require significant management resources to evaluate our internal control over financial reporting as required under Section 404 of the Sarbanes-Oxley Act, and any failure to comply or any adverse result from such evaluation may have an adverse effect on our stock price.
The other 38 risks
- Our failure to meet the continuing listing requirements of the NASDAQ Capital Market could result in a delisting of our securities.
- We will incur increased costs and demands upon management as a result of complying with the laws and regulations affecting public companies, which could adversely affect our operating results.
- We are eligible to be treated as a “smaller reporting company” within the meaning of the Securities Act, and we cannot be certain if the reduced disclosure requirements applicable to smaller reporting companies will make our common stock less attractive to investors.
- Risks Relating to Our Business and Industry
- We operate in a highly competitive environment, and if we are unable to compete with our competitors, our business, financial condition, results of operations, cash flows and prospects could be materially adversely affected.
- Unfavorable publicity or consumer perception of our products or similar products developed and distributed by other companies could have a material adverse effect on our reputation, which could result in decreased sales and fluctuations in our business, financial condition and results of operations.
- Our failure to appropriately and timely respond to changing consumer preferences and demand for new products could significantly harm our customer relationships and have a material adverse effect on our business, financial condition and results of operations.
- Future acquisitions or strategic investments and partnerships could be difficult to identify and integrate with our business, disrupt our business, and adversely affect our financial condition and results of operations.
- Failure to successfully integrate acquired businesses and their products and other assets into our Company, or if integrated, failure to further our business strategy, may result in our inability to realize any benefit from such acquisition.
- The failure to attract and retain key employees could hurt our business.
- We face substantial risk of product liability claims and potential adverse product publicity.
- We could incur obligations resulting from the activities of our independent distributors.
- If our independent distributors’ failure to comply with applicable advertising laws and regulations could adversely affect our financial conditions and results of operations.
- Risks Relating to Investing in Solana
- The launch of central bank digital currencies (“CBDCs”) may adversely impact our business.
- Absent federal regulations, there is a possibility that Solana may be classified as a “security.” Any classification of Solana as a “security” would subject us to additional regulation and could materially impact the operation of our business.
- If we were deemed to be an investment company under the 1940 Act, applicable restrictions likely would make it impractical for us to continue segments of our business as currently contemplated.
- We may be subject to regulatory developments related to crypto assets and crypto asset markets, which could adversely affect our business, financial condition, and results of operations.
- We may use the net proceeds from any offering by the Company to purchase additional Solana, the price of which has been, and will likely continue to be, highly volatile.
- Momentum pricing.
- The trading prices of many digital assets, including SOL, have experienced extreme volatility in recent periods and may continue to do so. Extreme volatility in the future, including declines in the trading prices of SOL, could have a material adverse effect on the value of the shares and the shares could lose all or substantially all of their value.
- Fluctuations in the price of Solana may significantly influence the market price of our common stock.
- A significant decrease in the market value of our Solana could adversely affect our ability to satisfy our financial obligations.
- There are numerous companies announcing their intention to build a digital asset treasury and specifically SOL treasury. This concentration of SOL holdings within a few treasury companies could cause the price of SOL to rapidly decline based on one or more of these treasury companies liquidating their position and could have a material adverse effect on the value of the shares and the shares could lose all or substantially all of their value.
- Our Solana holdings are less liquid than our existing cash and cash equivalents and may not be able to serve as a source of liquidity for us to the same extent as cash and cash equivalents.
- We are not subject to legal and regulatory obligations that apply to investment companies such as mutual funds and exchange-traded funds, or to obligations applicable to investment advisers.
- If we or our third-party service providers experience a security breach or cyberattack and unauthorized parties obtain access to our Solana, or if our private keys are lost or destroyed, or other similar circumstances or events occur, we may lose some or all of our Solana and our financial condition and results of operations could be materially adversely affected.
- We have limited history in generating staking revenues from Solana, which could adversely affect our business, financial condition and operating results.
- If the digital asset award or transaction fees for recording transactions on the Solana network are not sufficiently high to incentivize validators may demand high transaction fees, which could negatively impact the value of SOL and the value of the shares.
- Our trading orders may not be timely executed.
- Competition from other companies staking and utilizing Solana in their treasury plans.
- Competition from central bank digital currencies (“CBDCs”) and emerging payments initiatives involving financial institutions could adversely affect the price of SOL and other digital assets.
- Competition from the emergence or expansion of other digital assets may negatively influence the price of SOL and have an adverse impact on the value of the shares.
- We may fail to develop and execute successful investment or trading strategies.
- We may make, or otherwise be subject to, trade errors.
- We face other risks related to our Solana treasury strategy.
- SOL faces unique technical, governance and concentration risks that could materially affect its long-term viability.
- Solana validators are relatively small in number, which may lead to coordinated censorship.
- Our Solana validator reward yield is expected to decline over time and could have a material adverse effect on our financial results.
- Our SOL treasury strategy is dependent on the Solana Foundation and core development team.
Legal proceedings
From time to time, the Company may become involved in litigation relating to claims arising out of its operations in the normal course of business. The Company is not involved in any pending legal proceeding or litigation, and, to the best of its knowledge, no governmental authority is contemplating any proceeding to which we are a party or to which any of our properties are subject, which would reasonably be likely to have a material adverse effect on the Company, other than the following:
From time to time, we are a party to legal proceedings arising in the ordinary course of business. Other than the foregoing, the Company is not currently involved in any pending legal proceeding or litigation, and, to the best of its knowledge, no governmental authority is contemplating any proceeding to which we are a party or to which any of its properties is subject, which would reasonably be likely to have a material adverse effect on the Company.
The opening of Item 3, Legal Proceedings.6
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARUPEXI, INC. filings on SEC EDGAR
- 2
- 3SEC EDGARUPEXI, INC. 10-K for fiscal 2026
- 4SEC EDGARUPEXI, INC. filings on SEC EDGAR
- 5
- 6
- 7SEC EDGARUPEXI, INC. 10-K for fiscal 2020
- 8SEC EDGARUPEXI, INC. 10-K for fiscal 2021
- 9SEC EDGARUPEXI, INC. 10-K for fiscal 2022
- 10SEC EDGARUPEXI, INC. 10-K for fiscal 2023
- 11SEC EDGARUPEXI, INC. 10-K for fiscal 2024
- 12SEC EDGARUPEXI, INC. 10-Q for fiscal 2025
- 13SEC EDGARUPEXI, INC. 10-Q for fiscal 2026
- 14
- 15SEC EDGARRobert Hackett, President
- 16
- 17SEC EDGARBrian Benjamin Rudick, CSO
- 18
- 19SEC EDGARAndrew James Norstrud, Board member
- 20SEC EDGARGene Salkind, Board member
- 21SEC EDGARLawrence Dugan, Board member
- 22
- 23
- 24
- 25SEC EDGARRegulation FD disclosure
- 26SEC EDGAROther events
- 27SEC EDGARResults of operations
- 28SEC EDGARRegulation FD disclosure
- 29
- 30SEC EDGAROther events
- 31SEC EDGARListing notice or transfer
- 32SEC EDGAROther events
- 33
- 34
- 35
- 36SEC EDGARShareholder vote
- 37NasdaqNasdaq calendar
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54SEC EDGARRobert Hackett SC 13G on UPEXI, INC.
- 55
- 56
- 57SEC EDGARGene Salkind SC 13G/A on UPEXI, INC.
- 58